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Abstract
Background: Global efforts to scale-up malaria control interventions are gaining steam. These include the use of
Long-Lasting Insecticide Nets, Indoor Residual Spraying, Intermittent Preventive Treatment and Test, Treat and Track.
Despite these, the drive for malaria elimination is far from being realistic in endemic communities in Africa. This is
partly due to the fact that asymptomatic parasite carriage, not specifically targeted by most interventions, remains
the bedrock that fuels transmission. This has led to mass testing, treatment and tracking (MTTT) as an alternative
strategy to target asymptomatic individuals. We report the impact of MTTT on the prevalence of asymptomatic
malaria parasitaemia over a one-year period in Ghana, hypothesizing that implementing MTTT could reduce the
rate of asymptomatic parasitaemia.
Methods: A population of about 5000 individuals in seven communities in the Pakro sub-district of Ghana participated
in this study. A register was developed for each community following a census. MTTT engaged trained community-
based health volunteers who conducted house-to-house testing using RDTs every 4 months and treated positive cases
with Artemisinin–based Combination Therapy. Between interventions, community-based management of malaria was
implemented for symptomatic cases.
Results: MTTT Coverage was 98.8% in July 2017 and 79.3% in July 2018. Of those tested, asymptomatic infection with
malaria parasites reduced from 36.3% (1795/4941) in July 2017 to 32.9% (1303/3966) in July 2018 (p = 0.001). Prevalence
of asymptomatic parasitaemia among children under 15 years declined from 52.6% (1043/1984) in July 2017 to 47.5%
(820/1728) in July 2018 (p = 0.002). Implementing MTTT significantly reduced asymptomatic parasitaemia by 24% from
July 2017 to July 2018 after adjusting for age, ITN use and axillary temperature (OR = 0.76, CI = 0.67, 0.85 p≤ 0.001).
Conclusion: This study has demonstrated that implementing MTTT is feasible and could reduce the prevalence of
asymptomatic malaria parasitaemia in children under 15 years of age. Furthermore, the use of community-based health
volunteers could ensure high coverage at lower cost of implementation.
Trial registration: NCT04167566, Date 14/11/2019. Retrospective registration.
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Background
Over the last two decades, tremendous progress has
been made in the fight against malaria achieving signifi-
cant reduction in the global prevalence by 18%, mortality
and mobility in all age groups declined by 48%, while
mortality in children 2–10 years declined by 33% [1, 2].
This has resulted from a step-up in control efforts
toward its elimination [3]. Despite the recorded suc-
cesses, malaria still remains a significant public health
threat especially in endemic communities in Africa,
where most of the morbidity and mortality occurs.
Moreover, current evidence suggests a surge in preva-
lence and mortality between 2010 and 2016 in some
parts of sub-Saharan Africa [4]. In order to change the
present dynamics, there is a need to employ alternative
intervention strategies such as mass testing, treatment
and tracking (MTTT) [3, 5]. Malaria mass drug adminis-
tration (MDA) is an effective and well-known strategy
that has been found to drastically reduce prevalence, re-
verse mortality trends and led to elimination in specific
areas [6–13]. MDA was used in the malaria eradication
efforts at different points in history between 1950s –
1970s [6, 8, 14, 15].
MDA integrated with other approaches such as distri-
bution of LLINs and strengthening community based
health services and health workers, can accelerate mal-
aria elimination ([16–19]. MDA as an approach has
shown mixed results in the history of malaria elimin-
ation [8, 10, 20] and depends upon i) the targeted re-
gion’s epidemiology of malaria or transmission intensity;
ii) geographical characteristics of the malaria endemic
regions (islands where mobility of population is minimal
have cleared malaria, such as Aneityum, Taiwan); iii)
coverage of such an approach with effective community
engagement [21, 22]; and the challenges could be resist-
ance to antimalarials [19, 23–25] as well as lack of sup-
port from local authorities.
The factors that influenced the effectiveness of MDA
remain broadly valid today with similar malaria epidemi-
ology [15, 26, 27]. The renewed interest in malaria MDA
has stimulated an interest in mass testing, treatment and
tracking (MTTT) in order to limit unnecessary drug
pressure and resistance development. MTTT may face
similar challenges such as ineffective coverage and a lack
of community ownership etc., requiring the following
questions to be addressed; what level of community
coverage can be achieved through MTTT? Can MTTT
reduce malaria incidence? What will be the impact of
MTTT on malaria-related hospital visits? We demon-
strated in our earlier report that communities are willing
to fully engage and take ownership of the MTTT inter-
ventions [28].
In the context of present day challenges, attempts have
been made to formulate achievable malaria interventions
such as passive testing, treatment and tracking (T3) of
symptomatic cases at health facilities (standard of care),
providing whole populations with long lasting insecti-
cidal net (LLIN), intermittent preventive treatment in
children (IPTc) and pregnant women (IPTp) and sea-
sonal malaria chemoprevention (SMC) in sub-Sahara Af-
rica [1, 29]. Today, these interventions mostly target
passive cases detected or vulnerable groups such as
pregnant women and children [30].
Though the above mentioned interventions have been
shown to drastically reduce malaria prevalence, they re-
main insufficient in meeting the goal of reducing the
prevalence of malaria to elimination levels. Malaria elim-
ination is still far from being realistic in some endemic
communities especially in Africa, under the present
dispensation [24]. This is partly due to the fact that
asymptomatic parasite carriage, not specifically targeted
by most interventions, remains the bedrock that fuels
transmission [3]. Malaria control strategies targeting
asymptomatic malaria reservoir will have to deal with
the social and cultural factors. For example, how local
populations perceive the concept of sub-clinical/asymp-
tomatic malaria [21, 28]. In addition, strategies targeting
asymptomatic malaria would have to deal with intricate
plural health care in such settings, where normal health
seeking behaviour will be challenged. And such
approach would have to weave through and build on an
intricate health care seeking system through for ex-
ample, collaborating with both formal and informal
health care providers [31–34]. Given that cost is a major
limitation for implementing MDA of malaria, MTTT is
being proposed as an alternative strategy to target
asymptomatic individuals, mitigate the effect of resist-
ance development as well as limit unnecessary drug
pressure on those who are not carrying the parasite [35,
36]. Attempts to implement mass treatment in endemic
communities SMC are presently limited to children
under 5 in the Sahelian region of Africa. SMC has been
shown to reduce the burden of malaria in children below
5 years in Senegal, Mali and Burkina Faso and has fur-
ther been proven to be affordable if extended to 10 year
old children [29, 37–40]. While SMC has targeted the
Sahelian region with marked seasonal transmission,
strategies for reducing malaria parasitaemia towards
elimination in other endemic transmission areas of
Africa, which cover the broader population are needed.
Currently, symptomatic malaria still constitutes 38% of
outpatient consultation in hospitals in Ghana, while
asymptomatic malaria parasitaemia carriage is 25% in
children under 15 and above 40% in school-age children
[41–44]. Ghana adopted artesunate and amodiaquine as
first line drugs for the treatment of malaria since 2006.
It also adopted the T3 strategy in 2010, however, the re-
turn rate for malaria patients post-treatment is still
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below half [45]. Other drug interventions have included
the implementation of IPTc complemented by commu-
nity management of malaria in coastal communities,
which resulted in a reduction of asymptomatic parasit-
aemia by 90% in children under 5 [46]. However, there
are a number of unanswered questions, including:
whether MTTT intervention could be scaled-up to the
entire population since asymptomatic carriage is higher
in adults who have developed partial immunity or pre-
munition [47, 48]? What are the challenges to scaling up
the intervention to the adult population? What effect
MTTT would have on the prevalence of symptomatic
parasitaemia in the short-term? In this article, we report
findings from MTTT implementation across seven com-
munities in the Pakro sub-district of Ghana over a
period of 1 year, hypothesizing that implementing
MTTT complemented by CBMm could reduce the
prevalence of asymptomatic parasitaemia.
Methods
Study area
Pakro is one of five sub-districts in the Akwapim south dis-
trict health directorate (DHD) in the Eastern region of Ghana
[49]. The Akwapim south district lies within the semi-
equatorial climatic region, and experiences two rainfall sea-
sons in a year with an average rainfall of 125 cm to 200 cm.
The first rainy season begins from May to June with the
heaviest rainfall in June, whilst the second rainy season be-
gins from September to October. According to the Ghana
Statistical Service, the average household size in the Akwa-
pim South district is 4.0 whilst the average number of house-
holds per house or compound is estimated to be 1.6 [50].
The Pakro sub-district has an estimated population of 7889
and is bounded to the east by Akwapim North district; to
the north by Ayensuano district; and to the west by Nsawam
Adoagyiri Municipality. The sub-district is made up of 22
communities, and has 4 health care facilities (1 Health
Centre and 3 Community-based Health Planning Service
(CHPS) compounds) [49]. The Pakro Health Centre is one
of the 30 sentinel sites for monitoring malaria prevalence in
the country coordinated by the Noguchi Memorial Institute
for Medical Research. Malaria parasite positivity rate at the
Pakro Health Centre was 45.7% in 2014 while anaemia
among pregnant women at 36weeks of gestation was 21%
[49]. To undertake this study, 14 Community-Based Health
Volunteers (CBHVs) were specifically recruited and trained
for MTTT on the use of RDT test kits, treatment following
the malaria treatment guidelines, and follow-up as well as
reporting adverse events. CBHVs are community members
without a health background.
Selection of communities
Due to limited resources, seven communities were se-
lected for this study; Abease Newsite, Fante Town,
Zongo (Adjenase/Kweitey), Piem/odumsisi, Adesa, Sac-
chi/Tabankro and Odumtokro. These communities had
relatively higher population densities. In consultation
with the district health service, we considered a 5 km ra-
dius from the health facility and all 7 communities lo-
cated within that zone were selected. Additionally, they
are served by two public health facilities – the Pakro
sub-district Health Centre and the Zongo CHPS com-
pound. Patients from all 7 communities visit the health
facilities to seek health care. Staff from the Health facil-
ities undertake outreach services to the different
communities.
Study participants
The entire population of about 5000 from the seven se-
lected communities in Pakro sub-district was enrolled in
the study. This population size was obtained through the
household census. Community engagement activities to
sensitize the chiefs and the general population was con-
ducted at the beginning of the study through meetings
and durbars [41, 51]. All households were numbered,
and community registers developed to ensure tracking
of the participants. Each household was given a unique
identification code. Each individual within the household
was assigned a code that links them to a particular
household and community. After obtaining parental
informed consent, the children were enrolled but indi-
vidual assent and consent was obtained from the adoles-
cents and adults. (Fig. 1).
Inclusion criteria
All community members were included in the study
population. Willingness to participate was evident upon
completion and signing of a consent form by the individ-
ual, parent or guardian in the case of children.
Exclusion criteria
If an individual had a life-threatening illness (excluding
malaria) (s) he was excluded. However, all individuals in-
cluding those with clinical malaria signs who were
present during surveys were tested and when confirmed
to carry malaria parasites were treated.
MTTT of the population
In this study we considered asymptomatic parasitaemia
as a positive RDT test with no history of fever prior to
survey, axillary temperature of less than 37.5 °C and no
other signs and symptoms of malaria such as headache,
vomiting, abdominal pain, nausea or diarrhoea. The
entire population of the selected communities was
screened for the presence of malaria parasites using the
Ag P.f RDT (SD Bioline, Standard Diagnostics, Republic
of Korea) which detects histidinie-rich proteins II anti-
gens (HRP-2 Ag) specific to P. falciparum in human
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blood. The RDTs were obtained from the National Mal-
aria Control Programme. All participants confirmed to
be carrying malaria parasites were treated using an ACT
following the National Malaria Treatment Guidelines
[14]. To ensure that participants adhered to treatment
and to document adverse events, the first dose was dir-
ectly observed and participants followed-up at home to
confirm treatment adherence on days 1, 2, 3 and 7. Each
participant was observed for 5 minutes after treatment
administration to ensure that they retain the drug. For
children who vomited within 5 minutes of taking ACT,
the treatment was re-administered as it was assumed
that the drug had not been adequately absorbed.
The ACTs used in this study were also obtained from
the National Malaria Control Programme. The drug
regimen was changed at any given time depending on
what the NMCP was supplying across the country. For
instance, in July 2017, March 2018 and July 2018, we
used artesunate-amodiaquine (AA) while in November
2017 we used artemether lumefanthrine (AL).
Timely treatment of suspected febrile malaria cases in the
community
To facilitate MTTT, two CBHVs from each community
were recruited, trained and provided with the protocol,
RDTs and ACTs. Between one MTTT intervention and
the next, all children and adults reporting signs and
symptoms of malaria were tested by CBHVs using RDTs.
When confirmed to be carrying the malaria parasite, the
CBHVs treated the participant promptly using ACTs fol-
lowing the malaria management protocols provided. The
research team conducted monthly monitoring visits to
interact with CBHVs involved in community-based man-
agement to ensure that the protocol was being respected
and to replenish their stocks.
Data collection
To facilitate tracking and improve coverage, a commu-
nity register was developed. Communities were divided
into neighbourhoods and CBHVs were assigned a spe-
cific catchment area where they are well known. This
allowed the CBHVs to schedule appointments with a
particular household head before visiting to collect data.
This enabled the CBHVs to visit when most of the
household members were at home. In some instances,
the CBHVs had to visit the houses more than once to be
able to attend to all participants.
Following consent, axillary temperature of participant
was recorded using a digital thermometer and blood was
drawn from a finger prick for malaria testing. At base-
line, all participants were tested using RDTs (prevalence
survey) before treatment with ACT (intervention), when
positive. The data resulting from this work were stored
at the Noguchi Memorial Institute for Medical Research.
Hospital data was also collected during the intervention
months.
Data management and analysis
Data was analysed using SPSS (IBM SPSS Statistics 20,
United States). The unit of enrolment was the household.
Malaria prevalence was reported as proportion of partici-
pants confirmed during screening to be carrying the mal-
aria parasite, and they were stratified by demographic
variables such as age, sex and community. To determine
whether treating asymptomatic parasitaemia had an effect
on the incidence of symptomatic malaria during OPD
attendance, hospital data were compared to intervention
data. A Chi square statistic was used to compare preva-
lence of parasitaemia across age groups, gender and com-
munities at the 95% confidence level (p = 0.05). The p-
values represent changes between temporal time points.
Also, a regression analysis was conducted to test the effect
of factors such as timeline, age, temperature and use of
LLINs on the MTTT intervention.
Results
Coverage
Four MTTT interventions were conducted in July 2017,
November 2017, March 2018 and July 2018. Of the 5000
participants initially targeted across communities for
each intervention, coverage ranged from 77.8% (3891/
5000) to 98.8% (4941/5000) (Table 1). A total of 2669
participants received all four MTTTs (53%) and the me-
dian number of MTTTs participants received was 3. The
proportions represent those who were effectively
reached and tested. Females made up 50.4 and 52.4% of
Fig. 1 Implementation scheme of MTTT interventions in Pakro. MTTT interventions were conducted every 4 months. Between interventions, the
CBHVs conducted community-based management of malaria. The time indicates the intervention periods. This report compares the parasitaemia
prevalence at baseline to evaluation
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participants in July 2017 and July 2018, respectively
(Table 1). The fluctuation in coverage was largely due to
movement of people in and out of the intervention area,
and the proportion represents those who were effectively
reached. If a household was visited three times and the
participant could not be contacted, (s) he was considered
not available for the survey/intervention or reported to
have moved.
Asymptomatic parasitaemia prevalence
Considering the different time points across the inter-
vention period, asymptomatic malaria parasite carriage
Table 1 Parasite carriage across different communities at different time points in the Pakro sub-district
Characteristics Prevalence of asymptomatic parasitaemia among community members N (%)
July 2017 Survey n/N (%) November 2017 Survey n/N (%) March 2018 Survey n/N (%) July 2018 Survey n/N (%)
Community
Abease 282/888 (31.8) 124/712 (17.4) 77/709 (10.9) 161/721 (22.3)
Adesa 158/406 (38.9) 85/323 (26.3) 62/351 (17.7) 121/342 (35.4)
Adjanase 514/1342 (38.3) 191/957 (20.0) 283/1070 (26.5) 387/1037 (37.3)
Fante Town 543/1530 (35.5) 306/1238 (24.7) 347/1284 (27.0) 392/1236 (31.7)
Odumtokro 101/245 (41.2) 42/213 (19.7) 43/190 (22.6) 63/180 (35.0)
Piem 80/220 (36.4) 35/183 (19.3) 50/157 (31.9) 57/160 (35.6)
Sachi/Tabankro 117/310 (37.7) 75/265 (28.3) 75/277 (27.1) 122/290 (42.1)
Total 1795/4941 (36.3) 858/3891 (22.1) 937/4038 (23.2) 1303/3966 (32.9)
Coverage 4941/5000(98.8) 3891/5000(77.8) 4038/5000(80.8) 3966/5000 (79.3)
Table 2 Univariate analysis of effect of MTTT interventions on prevalence of asymptomatic malaria parasitaemia over the time
points July 2017 and 2018
Characteristics July 2017 Survey July 2018 Survey χ2 value P value
Community n/N (%) n/N (%)
Abease 282/888 (31.8) 161/721 (22.3) 17.1 < 0.001**
Adesa 158/406 (38.9) 121/342 (35.4) 1 0.319
Adjanase 514/1342 (38.3) 387/1037 (37.3) 0.2 0.624
Fante Town 543/1530 (35.5) 392/1236 (31.7) 4.4 0.037**
Odomtokro 101/245 (41.2) 63/180 (35.0) 1.7 0.193
Piem 80/220 (36.4) 57/160 (35.6) 0 0.882
Sachi/Tabankro 117/310 (37.7) 122/290 (42.1) 1.17 0.279
All Communities 1795 (36.3) 1303 (32.9) 11.71 0.001**
Age_group (years) n/N (%) n/N (%)
0–11 months 14/56 (25.0) 22/57 (38.6) 2.4 0.121
1–4 years 270/541 (49.9) 216/491 (44.0) 3.6 0.057
5–14 years 759/1387 (54.7) 582/1180 (49.3) 7.5 0.006**
15–45 years 5,852,092 (28.0) 360/1523 (23.6) 8.5 0.003**
46–65 years 129/640 (20.2) 97/544 (17.8) 1 0.310
> 65 years 38/225 (16.9) 26/171 (15.2) 0.2 0.352
Total # of < 15 1043/1984 (52.6) 820/1728 (47.5) 9.7 0.002**
Total # of≥ 15 752/2957 (25.4) 483/2238 (21.6) 10.4 0.001**
Mean axillary Temperature 36.0 36.2 < 0.001**
Use ITN
No 1595/4574 (34.9) 380/1166 (32.5) 0.0012 < 0.001
Yes 200/367 (54.5) 923/2800 (33.0)
All percentages represent proportions of parasite carriage compared to the population tested. The comparison is made only between July 2017 and July 2018
which depicts the same season
** Significance level at α =0.05
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was found to be 36.3% in July 2017, 22.1% in November
2017, 23.2% in March 2018 and 32.9% in July 2018.
These observations reflect the seasonality of malaria in
the district and across the country.
Comparative analysis between the two time points,
July 2017 to July 2018 revealed a decline in asymptom-
atic parasite carriage from 36.3% (1795/4941) to 32.9%
(1303/3966) (p = 0.001) (Tables 1 and 2)). The highest
level of community-specific prevalence of asymptomatic
parasitaemia per time point were 41.2, 28.3, 31.9 and
42.1% for July 2017, November 2017, March 2018 and
July 2018 respectively (Table 1). Parasite carriage signifi-
cantly declined in both Abease and Fante Town between
July 2017 and July 2018 (p < 0.0001 and p = 0.037 re-
spectively), but, the decline in the other communities
was not statistically significant. An increase in parasite
carriage was observed for Sachi/Tabankro from July
2017 to July 2018. However, this was not significant,
(Table 2).
The highest decline in parasitaemia carriage, was ob-
served in Abease while the lowest decline was observed
in Adesa. It is not clear what accounted for the hetero-
geneity as there were no other interventions in the area
at the time of this study. Asymptomatic parasitaemia
prevalence from July 2017 and July 2018 significantly de-
creased in both children and adults (p = 0.002 for < 15
children and p = 0.001 for ≥15 years) (Table 2). As per
age group, asymptomatic parasitaemia prevalence signifi-
cantly declined in the age groups 5–14 and 15–45 years,
but the decline was marginally significant in the age
group 1–4. This decline in parasitaemia was not signifi-
cant in the age groups 46–65 and > 65 years. An in-
crease in parasitaemia prevalence was observed among
the < 1 year old age group between July 2017 and 2018.
But this was not significant.
A logistic regression was performed to determine the
predictors of malaria parasitaemia and the magnitude of
the effect of the intervention on the outcome of interest,
which is malaria parasitaemia. Age, use of ITN and axil-
lary temperature were predictors of malaria parasitaemia
at the univariate level (α =0.05) (Table 3) and were
included as confounders in predicting the magnitude of
effect of the intervention on malaria parasitaemia preva-
lence. The intervention reduced parasitaemia by 24% a
year, after the mass treatment in July 2018, following
adjusting for confounders (OR = 0.76, CI = 0.67, 0.85 p
value ≤0.001) and by 9.4% a year, unadjusted. A unit in-
crease in age reduces malaria prevalence by 3% after
adjusting for confounders (OR = 0.97, CI = 0.97, 0.97, p
value≤0.001). The use of ITN was not a statistically sig-
nificant predictor of malaria parasitaemia prevalence
after adjusting for confounders (OR = 1.11, CI = 0.98,
1.26, p value ≤0.001). The implementation of MTTT re-
duced symptomatic parasitaemia by 9% from July 2017
to July 2018 after adjusting for age, though not statisti-
cally significant (OR = 0.91, CI = 0.67, 1.38 p value =
0.672) (Table 4).
Asymptomatic versus symptomatic malaria parasite
carriage
Records show that in July 2017, the Pakro Health Centre
was visited by 4.4% (219/4941) of the study population
who became febrile. Of these, 1.9% (96/4941) were con-
firmed to be positive for malaria. This means that 43.8%
(96/219) of all those presenting with fever were positive
for symptomatic parasitaemia carriage in July 2017 and
were treated. In July 2018, 5% (197/3966) of the popula-
tion that became febrile, visited the Health Centre and
2% (78/3966) of the population were confirmed to be
positive for malaria. Prevalence of symptomatic parasit-
aemia among those presenting with fever was 39.6% (78/
197) representing a 4.2% reduction in symptomatic para-
sitaemia between July 2017 and July 2018 (Table 5).
Implementing MTTT interventions significantly reduced
asymptomatic parasite carriage by 24% (OR = 0.76, CI =
0.67, 0.85 p = ≤0.001) after adjusting for age, use of ITNs
and axillary temperature, compared to a non-significant
reduction of 9% (OR = 0.91, CI = 0.67, 1.38, p = 0.672) in
confirmed symptomatic malaria cases who attended the
health facility over the same period (Table 5). This dem-
onstrates that implementing MTTT interventions could
reduce the asymptomatic malaria prevalence, which may
Table 3 Logistic regression for asymptomatic parasitaemia
Characteristics Unadjusted OR P value Adjusted OR P value
Timeline
July 2017 survey Ref 0.001 Ref < 0.001
July 2018 survey 0.86 (0.78, 0.94) 0.76 (0.67, 0.85)
Age (years) 0.97 (0.97, 0.97) < 0.001 0.97 (0.97, 0.97) < 0.001
Mean axillary Temperature 1.19 (1.14, 1.25) < 0.001 1.19 (1.12, 1.26) < 0.001
ITN Use
No Ref 0.034 0.086
Yes 0.92 (0.87, 0.99) 1.11 (0.98, 1.26)
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not necessarily be reflected to the same extent in the
outpatient consultations within the first year.
Confirmed parasitaemia was found to have decreased
across all the age groups except the 0–11months and
15–45 years age group where the proportion increased.
However, neither the observed increase nor decrease in
parasitaemia was significant in all age groups (Table 6).
Discussion
Coverage
Mass testing, treatment and tracking of the entire popu-
lation in an endemic area such as Pakro is suggested to
contribute to a decline in asymptomatic malaria parasite
carriage. Population coverage of more than 75% could
be achieved during MTTT interventions by using
CBHVs [6]. Though some level of population move-
ment in and out of the study communities was ob-
served, the communities are more or less established
with a relatively low degree of migration. This is prom-
ising for malaria elimination efforts through MTTT in
endemic areas [11]. However, there is a need to validate
these findings in a larger population by scaling up the
intervention.
Effect of MTTT on asymptomatic parasitaemia
The reasons for variation in parasite carriage and impact
of MTTT across communities is not clear. Malaria
prevalence across the communities was heterogeneous
and we suspect that differences in environmental factors
which play a role in malaria transmission in the locality
could be contributing to the heterogeneity in outcome.
Abease and Odomtokro are higher in altitude while the
rest of the communities are low lying, forming part of
the flood plain of the Densu River, which could be af-
fecting the continuous transmission in the area. Our re-
sults suggest that if MTTT is abandoned without
ensuring that the parasite is effectively cleared from the
community, transmission could easily be re-established
to previous levels within a short time [6]. This is be-
cause the drop in asymptomatic parasitaemia of 3.4%
between the two time points under consideration was
relatively low.
As expected, there was decline in asymptomatic mal-
aria for both children under-15 and those above 15
years. Participants aged 15 years and above recorded the
highest asymptomatic parasite carriage rate and inciden-
tally is the age group that does not usually experience fe-
brile illness. Therefore, reducing the malaria parasite
carriage in this age group could potentially propel a de-
cline in transmission, which could lead to a decline in
the burden of febrile malaria in the children under 15,
especially among the under-5 children who have not yet
developed partial immunity to the malaria parasite [3,
31, 32, 41, 52]. There were no significant differences in
the symptomatic burden in both children < 15 and those
above 15 years between July 2017 and July 2018. There
is need for more data to inform meaningful conclusions
from these observations.
Asymptomatic versus symptomatic parasite carriage
Registering more cases of asymptomatic parasite carriage
through MTTT, compared to symptomatic cases
through the standard of care (T3) at the health facilities
is of public health relevance. This observation suggests
Table 4 Logistic regression for symptomatic parasitaemia
Characteristics Unadjusted OR (CI) P value Adjusted OR (CI) P value
Timeline
July 2017 survey Ref 0.381 Ref 0.672
July 2018 survey 0.83 (0.57, 1.24) 0.91 (0.67, 1.38)
Age_group (years)
0–11 months Ref < 0.001 Ref < 0.001
1–4 years 1.72 (1.41, 2.11) < 0.001 0.67 (0.64, 6.91) 0.53
5–14 years 3.31 (2.70, 4.08) < 0.001 1.62 (0.44, 5.92) 0.469
15–45 years 0.72 (0.59, 0.89) 0.002 0.54 (0.15, 1.86) 0.328
46–65 years 0.46 (0.38, 0.58) < 0.001 0.31 (0.08, 1.16) 0.082
> 65 years 0.49 (0.40, 0.61) < 0.001 0.34 (0.09, 1.23) 0.111
Table 5 Comparative analysis of asymptomatic and symptomatic prevalence in the Pakro sub-district
MTTT Data (Asymptomatic parasitaemia) Hospital Data for clinical malaria (symptomatic parasitaemia)
RDT + Total tested % RDT + Total OPD attendance %
Jul-17 1795 4941 36.3 96 219 43.8
Jul-18 1303 3966 32.9 78 197 39.6
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that malaria control and intervention strategies should
consider asymptomatic parasitaemia as a public health
concern and a major hindrance to malaria elimination
efforts. Considering that 94% of the asymptomatic mal-
aria carriers in the study area did not become febrile
should probably suggest that malaria elimination pro-
grammes in endemic communities such as Ghana, may
require a change in strategy from targeting symptomatic
to asymptomatic parasite clearance. While clearing of
asymptomatic parasitaemia can lead to a decline in
transmission over time [3] and consequently reflect in a
reduction in malaria-related hospital attendance, the ef-
fect may or may not be very visible in the first years of
MTTT implementation. This is more-so if malaria-
related visits is considered as a lone indicator rather than
all-cause hospital visits [23, 53]. This finding is in sharp
contrast to the report by Halliday et al., [54] who re-
ported the absence of an impact on health following the
intermittent preventive treatment of school age children
in Kenya. It seems a public health dilemma, that in
Pakro less than 10% of the malaria parasite carriers actu-
ally visit health facilities for clinical management. Des-
pite this observation, the health facility complained that
during the MTTT interventions, there was a drastic drop
in the number of febrile cases attending the facility. This
was further confirmed by the perceptions of the commu-
nity members during focus group discussions, when they
stated that their level of hospital attendance had reduced
during that period [28]. It has been reported that a
decline in malaria episodes in Kenya was accompanied
by a concurrent decline in bacterial diseases [55]. The
observations in Kenya could potentially explain our ob-
servations in Pakro sub-District, though the rate of bac-
terial causes of hospitalizations was not determined in
this study.
Also, since malaria constitutes the bulk of OPD at-
tendance, eliminating malaria in endemic communi-
ties could pose other public health concerns which
need to be anticipated as other programmes seem to
depend on revenue generated from malaria visits to
run the health facilities [52]. As reported in our earl-
ier publication, implementing MTTT led to a
decrease in the internally generated revenue of the
Pakro Health Centre [28]. Rather than being a chal-
lenge, this is an important indicator of the outcome
of the study which could help inform reforms in the
health sector in the wake of efforts to eliminate mal-
aria in endemic and resource limited settings. This
could mean that under funded programmes in the
health sector, which depend on revenue generated
from malaria management in health facilities will
need to reconsider their options.
Limitations
Some of the limitations of this study include the follow-
ing: i) The duration of the study was rather short, enab-
ling minimal data collection which could not adequately
explain all the observation made in this study. Much
more extensive data need to be collected in future stud-
ies to enable more robust observations and conclusions.
ii) The effect of community-based management of mal-
aria by the CBHVs on the outcome of the study was not
assessed and quantified. This could have thrown more
light on the impact of MTTT in the communities stud-
ied. iii) The parasite status of participants who moved in
and out of the study communities between interventions
was not assessed to determine whether they returned
with new infections iv) We used only RDTs for testing
malaria parasitaemia. This means we might have missed
participants with low density parasitaemia which could
not be detected by the RDTs. These observations could
have impacted the results of the study. v) Also, we did
not have a control arm for this study. This could have
provided further insight to the outcome of this study.
This component will be included in future studies.
Conclusion
The findings of this study demonstrate that MTTT con-
tributed to a decline in asymptomatic malaria parasite
carriage among the population of the Pakro sub-district
of Ghana. It is feasible to attain more than 75% coverage
of MTTT complemented by community-based manage-
ment of malaria in Pakro and similar endemic areas. The
study also revealed that most parasite carriers in en-
demic communities do not become febrile, thus, more
people can be cleared of the parasite through MTTT
than the current facility-based consultations or standard
of care (T3) that focuses on symptomatic patients. Fur-
thermore, the results suggest that in the early stages of
implementing MTTT, reduction in asymptomatic para-
site carriage in the community may or may not immedi-
ately be reflected in malaria-related attendance at health
facilities in the short term.
Table 6 Confirmed symptomatic parasitaemia across all age
groups N (%)
Age group July 2017 Survey July 2018 Survey χ2 value P Value
0–11months 2/5 (40.0) 4/6 (66.7) 0.7822 0.567
1–4 years 28/60 (46.7) 16/38 (42.1) 0.1957 0.658
5–14 years 24/33 (72.7) 17/29 (58.6) 1.3713 0.242
15–45 years 26/73 (35.6) 23/51 (45.1) 1.1293 0.288
46–65 years 6/18 (33.3) 11/45 (24.4) 0.5156 0.473
> 65 years 10/30 (33.3) 7/28 (25.0) 0.4854 0.486
Total # of < 15 54/98 (55.1) 37/73 (50.7) 0.3279 0.567
Total # of ≥15 42/121 (34.7) 41/124 (33.1) 0.0741 0.785
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